Expertise in
19
conditions

Martin H. Schuler

Ruhrlandklinik
Essen, NW, DE 
Expertise in
19
conditions
Ruhrlandklinik
Essen, NW, DE 

Overview

Martin Schuler practices practicing medicine in Essen, Germany.

Mr. Schuler is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Endoscopy.

He is actively involved in clinical research, co-authoring 269 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Ruhrlandklinik
Essen, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib
Enrollment Status: Completed
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
View 1 Less Clinical Trial

269 Total Publications

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
Journal: Journal for immunotherapy of cancer
Published: July 31, 2026

Frequently Asked Questions about Martin H. Schuler

Is Martin H. Schuler a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Martin H. Schuler is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martin H. Schuler participate in research or clinical trials?

Yes. Martin H. Schuler has published 269 articles and abstracts on conditions like Lung Cancer. You can view a list of Martin H. Schuler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schuler's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile